Trevi Q1 net loss $7.3M; Phase 2 CANAL shows 52% placebo-adjusted cough reduction; $55M financing closed

Trevi Therapeutics, Inc.

2023-Q1 EPS reported -$0.24

Q1 2022 net loss $7.3M vs $8.4M prior year; R&D expenses $4.6M down from $5.6M.
Cash $29.1M at March 31; plus $55M gross from April private placement for Haduvio development.
Phase 2 CANAL interim (N=26): 77.3% reduction daytime cough vs 25.7% placebo (p<0.0001); enrollment ended early.
Full CANAL data expected Q3 2022; Phase 2b/3 PRISM (PN) top-line data expected Q2 2022.
Phase 2b/3 PRISM enrollment completed Jan 2022; data readout anticipated in current quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.